Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa. Opexa intends to use the net proceeds from the offering to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS and for general corporate purposes (including working capital, research and development, business development and operational purposes). Aegis Capital Corp. acted as sole book-running manager for the offering. The offering was made pursuant to a shelf registration statement on Form S-3 that was filed by Opexa with the Securities and Exchange Commission (SEC) and declared effective by the SEC on December 5, 2012.Copies of the prospectus supplement relating to and describing the terms of the offering are available on the SEC’s web site at http://www.sec.gov.Copies of the prospectus supplement relating to these securities may also be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, via telephone at (212) 813-1010, or via email at firstname.lastname@example.org.This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.About Opexa Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.